Novo Nordisk initiates patent suit to stop Ozempic copies

The firm wants to stop competitors from launching generic versions of Ozempic on the US market.

Photo: Novo Nordisk Pharmatech/PR

Danish pharmaceutical firm Novo Nordisk has filed a patent suit in order to prevent competitors from launching copies of Ozempic on the US market, Bloomberg News reports.

Ozempic is Novo Nordisk’s best-selling drug, with sales last year equating to 17 percent, or just under USD 3.7bn, of the company’s revenue.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs